115 related articles for article (PubMed ID: 9484869)
1. Antibacterial activity of grepafloxacin.
Wiedemann B; Heisig P
J Antimicrob Chemother; 1997 Dec; 40 Suppl A():19-25. PubMed ID: 9484869
[TBL] [Abstract][Full Text] [Related]
2. Grepafloxacin.
Wagstaff AJ; Balfour JA
Drugs; 1997 May; 53(5):817-24; discussion 825-7. PubMed ID: 9129868
[TBL] [Abstract][Full Text] [Related]
3. Antibacterial activities of grepafloxacin, ciprofloxacin, ofloxacin and fleroxacin.
Barry AL; Fuchs PC
J Chemother; 1997 Feb; 9(1):9-16. PubMed ID: 9106012
[TBL] [Abstract][Full Text] [Related]
4. The activity of grepafloxacin against respiratory pathogens in the UK.
Wise R; Andrews JM
J Antimicrob Chemother; 1997 Dec; 40 Suppl A():27-30. PubMed ID: 9484870
[TBL] [Abstract][Full Text] [Related]
5. Grepafloxacin in respiratory tract infections: are we ready to accept a quinolone for empirical treatment?
Norrby SR
J Antimicrob Chemother; 1997 Dec; 40 Suppl A():99-101. PubMed ID: 9484879
[No Abstract] [Full Text] [Related]
6. Safety profile of grepafloxacin compared with other fluoroquinolones.
Stahlmann R; Schwabe R
J Antimicrob Chemother; 1997 Dec; 40 Suppl A():83-92. PubMed ID: 9484877
[TBL] [Abstract][Full Text] [Related]
7. [Grepafloxacin (Vaxar)--innovative antibiotic for therapy of respiratory tract infections. Symposium: "Grepafloxacin--a new quinolone designed for respiratory tract infection. Lausanne/Switzerland, 25 May 1997].
Pneumologie; 1997 Sep; 51(9 Suppl):1-4. PubMed ID: 9417540
[No Abstract] [Full Text] [Related]
8. Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis.
Forrest A; Chodosh S; Amantea MA; Collins DA; Schentag JJ
J Antimicrob Chemother; 1997 Dec; 40 Suppl A():45-57. PubMed ID: 9484873
[TBL] [Abstract][Full Text] [Related]
9. Grepafloxacin--focus on respiratory infections.
Geddes AM
J Antimicrob Chemother; 1997 Dec; 40 Suppl A():1-4. PubMed ID: 9484866
[No Abstract] [Full Text] [Related]
10. Possible role for the new fluoroquinolones (levofloxacin, grepafloxacin, trovafloxacin, clinafloxacin, sparfloxacin, and DU-6859a) in the treatment of anaerobic infections: review of current information on efficacy and safety.
Goldstein EJ
Clin Infect Dis; 1996 Dec; 23 Suppl 1():S25-30. PubMed ID: 8953103
[TBL] [Abstract][Full Text] [Related]
11. Grepafloxacin: a review of its safety profile based on clinical trials and postmarketing surveillance.
Lode H; Vogel F; Elies W
Clin Ther; 1999 Jan; 21(1):61-74; discussion 1-2. PubMed ID: 10090425
[TBL] [Abstract][Full Text] [Related]
12. In vitro antibacterial activity and pharmacodynamics of new quinolones.
Dalhoff A; Schmitz FJ
Eur J Clin Microbiol Infect Dis; 2003 Apr; 22(4):203-21. PubMed ID: 12687416
[TBL] [Abstract][Full Text] [Related]
13. Quinolone activity against anaerobes.
Appelbaum PC
Drugs; 1999; 58 Suppl 2():60-4. PubMed ID: 10553708
[TBL] [Abstract][Full Text] [Related]
14. New fluoroquinolone antibiotics.
Drug Ther Bull; 1999 Jan; 37(1):6-8. PubMed ID: 10562769
[TBL] [Abstract][Full Text] [Related]
15. Randomized, double-blind study of grepafloxacin versus amoxycillin in patients with acute bacterial exacerbations of chronic bronchitis.
Langan CE; Cranfield R; Breisch S; Pettit R
J Antimicrob Chemother; 1997 Dec; 40 Suppl A():63-72. PubMed ID: 9484875
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic effect of the quinolone prodrug prulifloxacin against experimental urinary tract infections in mice.
Tomii Y; Ozaki M; Matsuda M; Honmura T; Nishimura I; Yamaguchi R; Adachi T; Okawa Y; Nishino T
Arzneimittelforschung; 1996 Dec; 46(12):1169-73. PubMed ID: 9006794
[TBL] [Abstract][Full Text] [Related]
17. The in-vitro activity of grepafloxacin against Chlamydia spp., Mycoplasma spp., Ureaplasma urealyticum and Legionella spp.
Ridgway GL; Salman H; Robbins MJ; Dencer C; Felmingham D
J Antimicrob Chemother; 1997 Dec; 40 Suppl A():31-4. PubMed ID: 9484871
[TBL] [Abstract][Full Text] [Related]
18. Antibacterial properties of AM-1155, a new 8-methoxy quinolone.
Hosaka M; Kinoshita S; Toyama A; Otsuki M; Nishino T
J Antimicrob Chemother; 1995 Aug; 36(2):293-301. PubMed ID: 8522459
[TBL] [Abstract][Full Text] [Related]
19. Pneumococcal resistance in the UK.
Goldsmith CE; Moore JE; Murphy PG
J Antimicrob Chemother; 1997 Dec; 40 Suppl A():11-8. PubMed ID: 9484868
[TBL] [Abstract][Full Text] [Related]
20. Randomized, double-blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia.
O'Doherty B; Dutchman DA; Pettit R; Maroli A
J Antimicrob Chemother; 1997 Dec; 40 Suppl A():73-81. PubMed ID: 9484876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
